Allergy drops have been used around the world for more than 60 years, and many studies show that allergy drops are safe and effective. Dosing levels and the route of administration are safe enough to effectively treat infants, children, and people suffering from chronic conditions that previously made them unable to receive immunotherapy via shots.
In fact, the World Health Organization has endorsed sublingual immunotherapy as a viable alternative to injection therapy.
The well-respected Cochrane Collaboration, the world’s most-trusted international organization dedicated to reviewing healthcare treatments, recently concluded allergy drop immunotherapy significantly reduced allergy symptoms and use of allergy medications.
The safety profile for sublingual immunotherapy is superior to injection based on research studies and patient treatment experience. Systemic reactions occur 3x less with sublingual, and there has never been and anaphylactic reaction (life threatening) recorded over the 30+ years of sublingual treatment.
Compliance has not been studied extensively. However, one large managed-care organization did find 50% of patients receiving allergy shots dropped out of therapy during the first year. In looking at sublingual compliance among patients in many of the studies identified previously, approximately 90% of patients complete their treatment.